Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.64 USD +3.11% Intraday chart for Traws Pharma, Inc. -4.62% -14.16%
Apr. 04 North American Morning Briefing : Focus Turns to -2- DJ
Apr. 04 Traws Pharma, Inc. Announces Chief Executive Office Changes CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Traws Pharma Announces New Employee Inducement Grants
AQ
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
AQ
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
AQ
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
AQ
Onconova Therapeutics Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity V. Other CDK4/6i's
AQ
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
AQ
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets Nineteenth Annual Emerging Growth Equity Conference
AQ
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
AQ
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
AQ
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
AQ
Poster Presentation Monday, Dec. 11th 6:00-8:00p PT
PU
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
AQ
Onconova Expands Leadership Team with Two Key Appointments
AQ
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
AQ
Encouraging Rigosertib Data Presented at EADV as Late Breaker
AQ
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
AQ
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)
AQ
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
AQ
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
AQ
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. News Traws Pharma, Inc.
  5. Press Releases